syntaxin binding protein 5Genealiases: LGL3 · LLGL3 · Nbla04300
Q-omics provides the consensus-scored STXBP5 profile across patient tissues and cancer cell-line models. STXBP5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STXBP5 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, STXBP5 protein abundance shows 25,995 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where STXBP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STXBP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STXBP5 survival associations across molecular data types. STXBP5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STXBP5 RNA expression–survival associations across cancer types. High STXBP5 expression shows unfavorable associations in ACC, CESC, KIRP, LIHC, MESO and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STXBP5 RNA expression.
This table summarizes STXBP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STXBP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STXBP5 shows lower tumor expression in COAD, KICH, READ and BRCA and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher STXBP5 RNA expression in tumor versus normal tissue (log2 FC = +0.676, t-test p < 0.001).
This table shows molecular features associated with STXBP5 in patient tissues and cancer cell lines. In patient samples, STXBP5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STXBP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
